cilostazol has been researched along with Myocardial Ischemia in 9 studies
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of the present study was to investigate whether cilostazol use is associated with a lower risk of incident dementia in Asian patients with IHD, and whether these effects differed based on sex." | 7.88 | Effect of Cilostazol on Incident Dementia in Elderly Men and Women with Ischemic Heart Disease. ( Jung, YS; Kim, MY; Lee, S; Noh, Y; Paik, HY; Shin, S; Son, SJ, 2018) |
| " We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population." | 7.85 | Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. ( Chang, YH; Chien, CY; Tai, SY; Yang, YH, 2017) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 7.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| "The goal of the present study was to investigate whether cilostazol use is associated with a lower risk of incident dementia in Asian patients with IHD, and whether these effects differed based on sex." | 3.88 | Effect of Cilostazol on Incident Dementia in Elderly Men and Women with Ischemic Heart Disease. ( Jung, YS; Kim, MY; Lee, S; Noh, Y; Paik, HY; Shin, S; Son, SJ, 2018) |
| " We examined the potential association between the use of cilostazol, an antiplatelet agent and cyclic adenosine monophosphate phosphodiesterase 3 inhibitor, and the risk of dementia in an Asian population." | 3.85 | Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study. ( Chang, YH; Chien, CY; Tai, SY; Yang, YH, 2017) |
| "Cilostazol (Pletal), a quinolinone derivative with a cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitory activity, was recently approved by the Food and Drug Administration for treatment of symptoms of intermittent claudication (IC)." | 3.70 | Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. ( Cone, J; Fong, M; Kambayashi, J; Liu, Y; Wang, S; Yoshitake, M, 2000) |
| " This systematic review assesses the efficacy and safety of adjunctive cilostazol to DAT in combination with DAT on reducing clinical adverse events." | 2.49 | Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. ( Ding, XL; Gao, J; Jiang, B; Miao, LY; Xie, C; Zhang, H; Zhang, JJ; Zhang, LL, 2013) |
| "However, the ratio of stroke to ischemic heart disease is still different between the East and West." | 1.33 | Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? ( Shinohara, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, MY | 1 |
| Noh, Y | 1 |
| Son, SJ | 1 |
| Shin, S | 1 |
| Paik, HY | 1 |
| Lee, S | 1 |
| Jung, YS | 1 |
| Tai, SY | 1 |
| Chien, CY | 1 |
| Chang, YH | 1 |
| Yang, YH | 1 |
| Lee, SP | 1 |
| Suh, JW | 1 |
| Park, KW | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Rha, SW | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Kwon, TG | 1 |
| Bae, JH | 1 |
| Kim, HS | 1 |
| Ding, XL | 1 |
| Xie, C | 1 |
| Jiang, B | 1 |
| Gao, J | 1 |
| Zhang, LL | 1 |
| Zhang, H | 1 |
| Zhang, JJ | 1 |
| Miao, LY | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kwon, JA | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Rho, YM | 1 |
| Douglas, JS | 1 |
| Holmes, DR | 1 |
| Kereiakes, DJ | 1 |
| Grines, CL | 1 |
| Block, E | 1 |
| Ghazzal, ZM | 1 |
| Morris, DC | 1 |
| Liberman, H | 1 |
| Parker, K | 1 |
| Jurkovitz, C | 1 |
| Murrah, N | 1 |
| Foster, J | 1 |
| Hyde, P | 1 |
| Mancini, GB | 1 |
| Weintraub, WS | 1 |
| Shinohara, Y | 1 |
| Liu, Y | 1 |
| Fong, M | 1 |
| Cone, J | 1 |
| Wang, S | 1 |
| Yoshitake, M | 1 |
| Kambayashi, J | 1 |
| Regensteiner, JG | 1 |
| Hiatt, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for cilostazol and Myocardial Ischemia
| Article | Year |
|---|---|
Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2013 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
2 trials available for cilostazol and Myocardial Ischemia
| Article | Year |
|---|---|
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Coronary stent restenosis in patients treated with cilostazol.
Topics: Aged; Angina, Unstable; Aspirin; Cilostazol; Coronary Restenosis; Double-Blind Method; Female; Human | 2005 |
5 other studies available for cilostazol and Myocardial Ischemia
| Article | Year |
|---|---|
Effect of Cilostazol on Incident Dementia in Elderly Men and Women with Ischemic Heart Disease.
Topics: Aged; Aged, 80 and over; Cilostazol; Cohort Studies; Dementia; Female; Humans; Male; Myocardial Isch | 2018 |
Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Cerebrovascular Disorders; Cilostazol; Cohort Studies; Dementia; Fem | 2017 |
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2004 |
Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy?
Topics: Aspirin; Brain Infarction; Cilostazol; Humans; Incidence; Japan; Myocardial Ischemia; Platelet Aggre | 2006 |
Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Topics: Adenosine; Animals; Blood Pressure; Cilostazol; Dose-Response Relationship, Drug; Heart Rate; Humans | 2000 |